Developer docs
API playgroundTry for free, no card

Search company profiles

Compass Bioinformatics

Full company profile

uuid0007bq5

Namestring
Compass Bioinformatics
Legal namestring
Compass Bioinformatics Inc.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Compass Bioinformatics, founded in 2015 and headquartered in Hsinchu, Taiwan, develops InheriNext, an AI-powered web-based platform that automates NGS data interpretation for inherited disease diagnostics. The platform ingests FASTQ or VCF outputs, performs secondary analysis (variant calling including SNPs, Indels, CNVs, and structural variants), and ranks candidate disease-causing variants in 3–15 minutes using a proprietary phenotype-genotype ML algorithm benchmarked at 98.6% top-10 sensitivity. The product suite comprises four modules — Workflow Runner (secondary analysis), Phenotype Gene Prioritizer (ML-based variant ranking under ACMG/AMP guidelines), PhenoVarDB (cohort database in Beta), and Expert (domain-specific LLM chatbot in Beta) — and is registered with the US FDA as a Class 1 Software as a Medical Device.

The company monetizes through three pricing structures: annual SaMD subscriptions, per-report usage-based pricing for variable-volume institutions, and multi-year collaborative partnerships with research organizations. Go-to-market is hybrid: a four-stage enterprise sales motion (demo → trial → pilot license → custom integration) combined with product-led self-serve demo booking and significant event presence at major genetics conferences (ASHG, ACMG, JSHG, JSPG). Customers are predominantly hospitals, medical centers, and rare disease research institutes; the company reports deployments across 40+ institutes in Japan, 10,000+ cases analyzed worldwide, and named anchor customers including Japan's National Cerebral and Cardiovascular Center, National Center of Neurology and Psychiatry, and National Center for Child Health and Development, alongside Taipei Medical University Shuang-Ho Hospital.

Compass Bioinformatics operates through three regional hubs — Taiwan (HQ and R&D), Japan (wholly-owned subsidiary Compass株式会社 with dedicated General Manager Ping-Cheng Hsiung), and the United States (Austin, TX office) — and is led by CEO Frank Ong and CPO/co-founder Eric Tsai. In September 2025, BRIM Biotechnology (TWSE:6885) acquired a 42% strategic stake for up to NT$150 million (~$4.6M USD), positioning Compass as the AI-genomics arm of a clinical-stage biopharma. Additional strategic alliances include Genomenon (Mastermind FLEX Data integration), Revvity (genomics collaboration), TMU Digital Health Translational Alliance, and MCBIOS.

Short descriptiontext

Compass Bioinformatics develops InheriNext, an AI-powered FDA-listed Class 1 SaMD platform that automates NGS variant interpretation for rare disease diagnostics, serving hospitals, medical centers, and research laboratories across Taiwan, Japan, and the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHsinchu, Taiwan
HQ citystring
Hsinchu
HQ countrystring
Taiwan
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
NGS analysis software, clinical genomics platform, variant interpretation, rare disease diagnostics, bioinformatics SaaS
Industry5 codes
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code4 codes
  • Medical and Diagnostic Laboratories6215
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Medical Laboratories8071
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Genomics Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Software as Medical Device (SaMD) Subscriptions
TypeSubscription Recurring
Description

Annual license agreements for InheriNext platform access. US FDA listed Class 1 SaMD enabling clinical deployment. Subscription-based recurring revenue model.

compassbioinfo.com
2Per-Report Pricing
TypeUsage Based
Description

Usage-based pricing option where customers pay per genetic analysis report generated. Flexible model for institutions with variable testing volumes.

compassbioinfo.com
3Collaborative Partnerships
TypeSubscription Recurring
Description

Custom partnership arrangements with academic institutions and research organizations including data integration and platform customization services.

compassbioinfo.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Annual License - Subscription model for ongoing platform access
ModelSubscriptionBilling cadenceAnnual
Notes

Annual subscription license for InheriNext platform access; includes workflow runner, phenotype gene prioritizer, PhenoVarDB, and expert module access

compassbioinfo.com
2Per-Report - Usage-based pricing for flexible testing volumes
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Pay-per-report model optimized for institutions with variable genetic testing volumes; margin-sensitive pricing for large-scale genetic diagnoses

compassbioinfo.com
3Collaborative Partnership - Custom arrangements for research institutions
ModelHybridBilling cadenceMulti-year contract
Notes

Custom partnership arrangements including report generation, panel support, and IT integrations; tailored to specific institutional requirements

compassbioinfo.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1InheriNext®
Description

AI-powered rare disease genetic diagnostic platform for NGS data interpretation, variant ranking, and clinical reporting

compassbioinfo.com
+1 more record
Core offering1 text field

Compass Bioinformatics develops InheriNext®, an AI-powered next-generation sequencing (NGS) genomic analysis platform built to automate and accelerate rare disease diagnostics. The platform combines phenotype-driven gene prioritization, AI-based variant ranking, ACMG-compliant interpretation, and clinical reporting for clinical geneticists, molecular pathologists, and laboratory directors in hospital and reference lab settings, and holds US FDA Class 1 SaMD regulatory listing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 98.6% sensitivity for identifying causative variants within top 10 ranked variants
+4 more records
Product overview1 text field

Compass Bioinformatics offers a modular AI-powered genomic analysis platform called InheriNext, purpose-built for inherited disease diagnostics and clinical research. The platform is composed of a core AI-driven variant interpretation engine (InheriNext) plus four interchangeable modules: Workflow Runner handles secondary NGS analysis (FASTQ-to-VCF conversion); Phenotype Gene Prioritizer applies ML-based phenotype-genotype ranking to identify and rank causative variants; PhenoVarDB (in Beta) provides cohort database management and cross-patient variant matching; and Expert (in Beta) adds a conversational LLM interface for variant interpretation assistance. The platform is US FDA listed as a Class 1 Software as a Medical Device (SaMD) and is actively used in collaborations with medical centers across Taiwan, Japan, and the United States.

Product and service1 record
1InheriNext®
CategoryClinical Genomics Software
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-23
Description

Strategic partnership integrating Genomenon's Mastermind FLEX Data into InheriNext platform. Mastermind FLEX Data includes expertly curated gene and variant-level content with indexed variant-level information. The integration brings unparalleled genomic evidence to leading institutes across US, Japan, and beyond, elevating InheriNext's variant interpretation capabilities with continuous literature-based evidence updates.

2MidSouth Computational Biology and Bioinformatics Society (MCBIOS)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-08-22
Description

Alliance partnership hosting educational webinars on variant analysis and AI in genomics discovery. MCBIOS advances bioinformatics and computational biology by connecting scientists, facilitating collaboration, promoting education, and supporting trainees in the field.

compassbioinfo.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-08-07
Description

Three-way partnership with TMU DHT Industry-Academic Alliance and Ministry of Health and Welfare Shuang-Ho Hospital Rare Disease Centre. Aimed at advancing precision medicine, genetic testing, and actionable clinical strategies for inherited diseases. Event held at TMU Biodesign Centre with over 50 leading medical professionals. Partnership to leverage big data and polygenic risk scores for clinical decision support systems.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Cloud-based genomic data platform used by clinical and research organizations for NGS analysis pipelines; broader infrastructure layer with overlapping clinical genomics capabilities.

TypeDirect peer
Description

AI-driven clinical genomics platform for NGS data interpretation across rare disease, oncology, and hereditary disorders. Most direct competitor in multi-omics variant interpretation for hospitals and clinical labs.

TypeOthers
Description

Genomic literature evidence partner (Mastermind FLEX) and parent of Fabric Genomics. Functions as both an ecosystem data supplier and a competitive platform via Fabric, making it a critical adjacent relationship.

4Tempus
TypeBroad incumbent
Description

Large AI-driven precision medicine platform with clinical NGS interpretation capabilities across oncology and rare disease, serving hospital systems with broader data analytics portfolio.

TypeDirect peer
Description

Clinical genomic analysis platform for rare disease and inherited disorder variant interpretation, directly competing in the same hospital/lab market with AI-augmented workflows.

TypeDirect peer
Description

Genomic data analysis and interpretation platform serving hospitals, research institutions, and pharma with integrated NGS workflows and cohort tools.

TypeBroad incumbent
Description

Sequencing giant offering DRAGEN secondary analysis and BaseSpace clinical interpretation apps, providing integrated NGS workflows that compete end-to-end with standalone platforms like InheriNext.

TypeDirect peer
Description

AI-powered clinical NGS interpretation platform for rare disease diagnostics; notably now part of Genomenon, which is Compass's own data partner, making this both a peer and a closely-linked ecosystem player.

TypeDirect peer
Description

Genomic analysis software for clinical research and NGS variant annotation/interpretation, with comparable enterprise sales motion to hospital labs and research institutions.

10PierianDx (Elsevier)
TypeDirect peer
Description

Clinical genomics interpretation platform for hereditary disease and oncology NGS, serving hospital systems and reference labs with variant interpretation workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Compass Bioinformatics

Clinical Genomics Softwarecompassbioinfo.com

Compass Bioinformatics develops InheriNext, an AI-powered FDA-listed Class 1 SaMD platform that automates NGS variant interpretation for rare disease diagnostics, serving hospitals, medical centers, and research laboratories across Taiwan, Japan, and the United States.

What Compass Bioinformatics does

Compass Bioinformatics, founded in 2015 and headquartered in Hsinchu, Taiwan, develops InheriNext, an AI-powered web-based platform that automates NGS data interpretation for inherited disease diagnostics. The platform ingests FASTQ or VCF outputs, performs secondary analysis (variant calling including SNPs, Indels, CNVs, and structural variants), and ranks candidate disease-causing variants in 3–15 minutes using a proprietary phenotype-genotype ML algorithm benchmarked at 98.6% top-10 sensitivity. The product suite comprises four modules — Workflow Runner (secondary analysis), Phenotype Gene Prioritizer (ML-based variant ranking under ACMG/AMP guidelines), PhenoVarDB (cohort database in Beta), and Expert (domain-specific LLM chatbot in Beta) — and is registered with the US FDA as a Class 1 Software as a Medical Device.

The company monetizes through three pricing structures: annual SaMD subscriptions, per-report usage-based pricing for variable-volume institutions, and multi-year collaborative partnerships with research organizations. Go-to-market is hybrid: a four-stage enterprise sales motion (demo → trial → pilot license → custom integration) combined with product-led self-serve demo booking and significant event presence at major genetics conferences (ASHG, ACMG, JSHG, JSPG). Customers are predominantly hospitals, medical centers, and rare disease research institutes; the company reports deployments across 40+ institutes in Japan, 10,000+ cases analyzed worldwide, and named anchor customers including Japan's National Cerebral and Cardiovascular Center, National Center of Neurology and Psychiatry, and National Center for Child Health and Development, alongside Taipei Medical University Shuang-Ho Hospital.

Compass Bioinformatics operates through three regional hubs — Taiwan (HQ and R&D), Japan (wholly-owned subsidiary Compass株式会社 with dedicated General Manager Ping-Cheng Hsiung), and the United States (Austin, TX office) — and is led by CEO Frank Ong and CPO/co-founder Eric Tsai. In September 2025, BRIM Biotechnology (TWSE:6885) acquired a 42% strategic stake for up to NT$150 million (~$4.6M USD), positioning Compass as the AI-genomics arm of a clinical-stage biopharma. Additional strategic alliances include Genomenon (Mastermind FLEX Data integration), Revvity (genomics collaboration), TMU Digital Health Translational Alliance, and MCBIOS.

Compass Bioinformatics firmographics

Firmographics
Name
Compass Bioinformatics
Legal name
Compass Bioinformatics Inc.
Website
https://compassbioinfo.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Compass Bioinformatics develops InheriNext, an AI-powered FDA-listed Class 1 SaMD platform that automates NGS variant interpretation for rare disease diagnostics, serving hospitals, medical centers, and research laboratories across Taiwan, Japan, and the United States.
Ownership category
akta.pro rank

Compass Bioinformatics industry classification

Industry
Product category
Clinical Genomics Software
NAICS
Medical and Diagnostic Laboratories (6215), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • NGS analysis software
  • Clinical genomics platform
  • Variant interpretation
  • Rare disease diagnostics
  • Bioinformatics SaaS

Where Compass Bioinformatics is headquartered

Location

Headquarters

HQ city
Hsinchu
HQ country
Taiwan
HQ region
Asia

Offices3 records

Markets served

Compass Bioinformatics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Software as Medical Device (SaMD) Subscriptions: Annual license agreements for InheriNext platform access. US FDA listed Class 1 SaMD enabling clinical deployment. Subscription-based recurring revenue model.
  2. Per-Report Pricing: Usage-based pricing option where customers pay per genetic analysis report generated. Flexible model for institutions with variable testing volumes.
  3. Collaborative Partnerships: Custom partnership arrangements with academic institutions and research organizations including data integration and platform customization services.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualAnnual License - Subscription model for ongoing platform access
Usage-basedPay-as-you-goPer-Report - Usage-based pricing for flexible testing volumes
HybridMulti-year contractCollaborative Partnership - Custom arrangements for research institutions

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Compass Bioinformatics product offering

Product offering

Core offering

Compass Bioinformatics develops InheriNext®, an AI-powered next-generation sequencing (NGS) genomic analysis platform built to automate and accelerate rare disease diagnostics. The platform combines phenotype-driven gene prioritization, AI-based variant ranking, ACMG-compliant interpretation, and clinical reporting for clinical geneticists, molecular pathologists, and laboratory directors in hospital and reference lab settings, and holds US FDA Class 1 SaMD regulatory listing.

Product overview

Compass Bioinformatics offers a modular AI-powered genomic analysis platform called InheriNext, purpose-built for inherited disease diagnostics and clinical research. The platform is composed of a core AI-driven variant interpretation engine (InheriNext) plus four interchangeable modules: Workflow Runner handles secondary NGS analysis (FASTQ-to-VCF conversion); Phenotype Gene Prioritizer applies ML-based phenotype-genotype ranking to identify and rank causative variants; PhenoVarDB (in Beta) provides cohort database management and cross-patient variant matching; and Expert (in Beta) adds a conversational LLM interface for variant interpretation assistance. The platform is US FDA listed as a Class 1 Software as a Medical Device (SaMD) and is actively used in collaborations with medical centers across Taiwan, Japan, and the United States.

Differentiator

Problem solved

Functional benefit

Brands

  • InheriNext®: AI-powered rare disease genetic diagnostic platform for NGS data interpretation, variant ranking, and clinical reporting
  • InheriNext® Edge

Products and services

  • InheriNext®

Quantifiable outcome

  • 98.6% sensitivity for identifying causative variants within top 10 ranked variants
  • +4 more outcomes

Companies that use Compass Bioinformatics

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles2 records

Compass Bioinformatics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature7 records

Compass Bioinformatics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core, minor and flagship.

  • GenomenoncoreTechnology or Integration · 23 September 2025Strategic partnership integrating Genomenon's Mastermind FLEX Data into InheriNext platform. Mastermind FLEX Data includes expertly curated gene and variant-level content with indexed variant-level information. The integration brings unparalleled genomic evidence to leading institutes across US, Japan, and beyond, elevating InheriNext's variant interpretation capabilities with continuous literature-based evidence updates.
  • MidSouth Computational Biology and Bioinformatics Society (MCBIOS)minorStrategic or Co-development Partner · 22 August 2025Alliance partnership hosting educational webinars on variant analysis and AI in genomics discovery. MCBIOS advances bioinformatics and computational biology by connecting scientists, facilitating collaboration, promoting education, and supporting trainees in the field.
  • Taipei Medical University Digital Health Translational (DHT) Industry-Academic AllianceflagshipStrategic or Co-development Partner · 7 August 2025Three-way partnership with TMU DHT Industry-Academic Alliance and Ministry of Health and Welfare Shuang-Ho Hospital Rare Disease Centre. Aimed at advancing precision medicine, genetic testing, and actionable clinical strategies for inherited diseases. Event held at TMU Biodesign Centre with over 50 leading medical professionals. Partnership to leverage big data and polygenic risk scores for clinical decision support systems.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Compass Bioinformatics competitors and assessment

Company assessment

Broad incumbents

  • DNAnexus: Cloud-based genomic data platform used by clinical and research organizations for NGS analysis pipelines; broader infrastructure layer with overlapping clinical genomics capabilities.
  • Tempus: Large AI-driven precision medicine platform with clinical NGS interpretation capabilities across oncology and rare disease, serving hospital systems with broader data analytics portfolio.
  • Illumina (DRAGEN, BaseSpace): Sequencing giant offering DRAGEN secondary analysis and BaseSpace clinical interpretation apps, providing integrated NGS workflows that compete end-to-end with standalone platforms like InheriNext.

Direct peers

  • SOPHiA Genetics: AI-driven clinical genomics platform for NGS data interpretation across rare disease, oncology, and hereditary disorders. Most direct competitor in multi-omics variant interpretation for hospitals and clinical labs.
  • Congenica: Clinical genomic analysis platform for rare disease and inherited disorder variant interpretation, directly competing in the same hospital/lab market with AI-augmented workflows.
  • BC Platforms: Genomic data analysis and interpretation platform serving hospitals, research institutions, and pharma with integrated NGS workflows and cohort tools.
  • Fabric Genomics (Genomenon): AI-powered clinical NGS interpretation platform for rare disease diagnostics; notably now part of Genomenon, which is Compass's own data partner, making this both a peer and a closely-linked ecosystem player.
  • Golden Helix: Genomic analysis software for clinical research and NGS variant annotation/interpretation, with comparable enterprise sales motion to hospital labs and research institutions.
  • PierianDx (Elsevier): Clinical genomics interpretation platform for hereditary disease and oncology NGS, serving hospital systems and reference labs with variant interpretation workflows.

Others

  • Genomenon: Genomic literature evidence partner (Mastermind FLEX) and parent of Fabric Genomics. Functions as both an ecosystem data supplier and a competitive platform via Fabric, making it a critical adjacent relationship.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compass Bioinformatics social profiles

Digital presence

Compass Bioinformatics compliance and trust

Trust signal

Compliance1 record

Compass Bioinformatics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Compass Bioinformatics leadership team

Management profile

Number of profiles

Profiles5 records

Compass Bioinformatics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Compass Bioinformatics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Compass Bioinformatics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Compass Bioinformatics

What does Compass Bioinformatics do?

Compass Bioinformatics develops InheriNext®, an AI-powered next-generation sequencing (NGS) genomic analysis platform built to automate and accelerate rare disease diagnostics. The platform combines phenotype-driven gene prioritization, AI-based variant ranking, ACMG-compliant interpretation, and clinical reporting for clinical geneticists, molecular pathologists, and laboratory directors in hospital and reference lab settings, and holds US FDA Class 1 SaMD regulatory listing.

Is Compass Bioinformatics a public or private company?

Compass Bioinformatics is a private company. It is classified as corporate owned and is currently operating.

When was Compass Bioinformatics founded?

Compass Bioinformatics was founded in 2015. It employs 11 to 50 people.

Where is Compass Bioinformatics based?

Compass Bioinformatics is headquartered in Hsinchu, Taiwan, in the Asia region.

How does Compass Bioinformatics make money?

Three revenue lines are on record. Software as Medical Device (SaMD) Subscriptions are the primary driver. The others are per-Report Pricing and collaborative Partnerships.

Who are Compass Bioinformatics's main competitors?

Broad incumbents on record are DNAnexus, Tempus and Illumina (DRAGEN, BaseSpace). Direct peers are SOPHiA Genetics, Congenica, BC Platforms, Fabric Genomics (Genomenon), Golden Helix and PierianDx (Elsevier). Genomenon is listed as an others.

Does Compass Bioinformatics have an API?

No public API is recorded for Compass Bioinformatics.

What industry is Compass Bioinformatics in?

Compass Bioinformatics's product category is Clinical Genomics Software. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGenomenon and Compass Bioinformatics Partner to Transform Genomic Diagnostics in the U.S. and JapanGenomenon, a genomic intelligence company based in Ann Arbor, Michigan, announced a strategic partnership with Compass Bioinformatics to integrate its Mastermind FLEX Data into Compass's InheriNext platform for genetic disease diagnostics. The collaboration combines Genomenon's curated gene and variant-level content with Compass's AI-powered genomic analysis, enhancing variant interpretation for clinicians and researchers. The partnership expands Genomenon's presence in Japan and Asia while strengthening InheriNext for U.S. users, with the platform already deployed in over 40 leading rare disease research and diagnostic institutes in Japan.YahooGenomenon and Compass Bioinformatics Partner to Transform Genomic Diagnostics in the U.S. and JapanGenomenon and Compass Bioinformatics announced a partnership integrating Genomenon's Mastermind FLEX Data into Compass's InheriNext platform for genetic disease diagnostics. The integration strengthens variant interpretation with ACMG-guided evidence and expands Genomenon's presence in Japan and Asia. InheriNext has been deployed in over 40 institutes in Japan.GenomenonGenomenon and Compass Bioinformatics Partner to Transform Genomic Diagnostics in the U.S. and JapanGenomenon and Compass Bioinformatics announced a strategic partnership to integrate Genomenon’s Mastermind FLEX Data into Compass Bioinformatics’ InheriNext platform for genetic disease diagnostics. This collaboration aims to enhance variant interpretation capabilities for clinicians in the U.S. and Japan while expanding Genomenon’s market presence in Asia.GenomenonGenomenon, Compass Bioinformatics Partner to Integrate Genomic Data, Analysis PlatformsGenomenon and Compass Bioinformatics have partnered to integrate their genomic data and analysis platforms. This collaboration aims to enhance the capabilities of genomic research for their users. Specific strategic implications of the partnership were not detailed in the article.